Amarin Corp Plc (AMRN)

[couldbebetter]

A price increase or not for Vascepa may have to consider many factors
such as the future pricing of Vascepa in foreign markets such as Canada
(which will demand a discounted price.) AMRN should have a long-term
pricing strategy which considers all future factors. Amgen has already
lowered the price of Repatha (a PCKS-9) to around $2500. Given that
Vascepa is far more effective (and a patient could have both) one has
to wonder if that will be a common practice in the future. ( I think
Kiwi is on both Repatha and Vascepa.) Then, there is Adam Feuersein
who suggested that AMRN should be acquired by Amgen. I bring this up
here because I wonder if Amgen views Vascepa as a "threat" or as the
better drug of the two. If you are Amgen, how do you compete against
all of the other PCKS-9's and how do you deal with Vascepa (a much
superior medication.) One could argue that most patients on a PCKS-9
should also be on Vascepa. I read that the reason why Amgen cut its
price on Repatha was because of the other PCKS-9's. Is that the reason
or did they cut it to be priced lower than Vascepa? What is interesting
is that the combined price of Repatha and Vascepa are now less than half
the price of what Repatha was priced at initially. I also wonder why
Adam Feuerstein used Amgen as his example for why AMRN should be sold.
Did AF just pull it out of his ***, or does he have some other reason
to suggest such a tie-up?